Clear Cell Ovarian Cancer — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Arrange bone-marrow analysis and/or blood cytogenetic testing
Persistent severe haematological toxicity after a four-week olaparib interruption triggers bone-marrow and/or cytogenetic investigation for MDS/AML. Restarting either PARP inhibitor without explaining the cytopenia is unsafe; G-CSF does not replace diagnostic evaluation, and the SmPC does not require waiting 12 weeks.
Reference: Lynparza 150 mg UK SmPC. https://www.medicines.org.uk/emc/product/9488/smpc